£1.7 Million Fellowship Awarded to Investigate Silicosis in UK Workers

Imperial College researcher secures funding to study the growing public health threat of silicosis in the artificial stone worktop industry.

Generic image of a microscope slide with dust particles.
AI

Generic image of a microscope slide with dust particles.

Dr Jo Feary, a Senior Clinical Research Fellow at Imperial's National Heart and Lung Institute, has been awarded a £1.7 million fellowship to conduct the first UK study on silicosis in workers exposed to silica dust, particularly in the artificial stone worktop fabrication industry.

The four-year fellowship, funded by the National Institute for Health and Care Research (NIHR) and the Colt Foundation, will address the urgent and growing public health threat of silicosis. Once considered a disease of the past, silicosis has re-emerged due to the popularity of artificial stone worktops. Around 60 workers have been diagnosed in the UK since 2023, with numbers increasing monthly. Many are treated at a specialist clinic at the Royal Brompton Hospital, where Dr Feary works as an Honorary Consultant.
Silicosis is a progressive lung disease caused by inhaling respirable crystalline silica dust. While previously workers developed the disease after 15-20 years of exposure, the high concentration of silica in artificial stone and limited dust control measures mean workers can develop it after just one year. This emerging global epidemic has seen over 6,000 cases reported by the end of 2025 across twelve countries. Australia banned artificial stone products in 2024 after over 1,000 diagnoses and related deaths.
Dr Feary identified what is believed to be the UK’s first recognised case of silicosis from artificial stone in late 2023. By February 2024, eight more patients were diagnosed. Her team published initial findings in Thorax in August 2024. "Since that first patient, we have seen a month-by-month increase in silicosis cases at our Brompton clinic," Dr Feary stated. "The average age of patients is around 40, but many are in their twenties, with young families."
There is no effective treatment for silicosis, and prognosis depends on the stage at diagnosis. Advanced stages can have catastrophic consequences. "When silicosis is caught in its earliest stages, before symptoms develop, the patient may remain well for many years provided they are no longer exposed to silica," Dr Feary explained. "But if they present with more advanced disease, it can progress rapidly, with lung transplantation being the only real treatment option."
The fellowship will facilitate the ARTIST study (Understanding silicosis in ARTificial STone). Dr Feary and her team will visit worktop fabrication companies to invite asymptomatic workers for lung scans and tests. They aim to identify the number of workers in the UK industry, the proportion with silicosis, measure exposure levels, and investigate exposure–response relationships. "Whilst we are aware of 60 cases in the UK to date, we estimate... that the real number of people living with silicosis in this country is likely to be in the hundreds, if not thousands," Dr Feary said. "If we don’t identify them quickly enough, more lives will be unnecessarily lost to this disease."
Identifying silicosis cases is challenging due to lack of symptoms, limited health surveillance access, and potential misdiagnosis. "This is why it is important to study workers directly in their workplaces, rather than relying on patients who have already been diagnosed with silicosis in hospital," Dr Feary explained. Challenges include worker concerns about employment implications following a diagnosis. Dr Feary has been raising awareness among policymakers and healthcare professionals, advising the All-Party Parliamentary Group for Respiratory Health. "Silicosis is a preventable industrial disease, but in 2026 we are seeing an alarming increase in cases, particularly in young and vulnerable men. Some have already died," she stated. "Addressing it will require a multifaceted approach... A key part of this is to obtain high-quality data from the UK to inform workplace practices and national policies. I am delighted to receive this funding, and to be able to move this research forward. I really hope that its impact will be far-reaching, and ultimately, save lives."
Based on information from the official source: Imperial College London (18/11/2026)